Finch Therapeutics Group (FNCH) Competitors $12.05 0.00 (0.00%) As of 10/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock FNCH vs. HOWL, COEP, GANX, ELYM, RLMD, AADI, LITS, ABVC, INKT, and CRVOShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Werewolf Therapeutics (HOWL), Coeptis Therapeutics (COEP), Gain Therapeutics (GANX), Eliem Therapeutics (ELYM), Relmada Therapeutics (RLMD), Aadi Bioscience (AADI), Lite Strategy (LITS), ABVC BioPharma (ABVC), MiNK Therapeutics (INKT), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. Its Competitors Werewolf Therapeutics Coeptis Therapeutics Gain Therapeutics Eliem Therapeutics Relmada Therapeutics Aadi Bioscience Lite Strategy ABVC BioPharma MiNK Therapeutics CervoMed Werewolf Therapeutics (NASDAQ:HOWL) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment. Which has more risk & volatility, HOWL or FNCH? Werewolf Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Which has stronger earnings and valuation, HOWL or FNCH? Werewolf Therapeutics has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWerewolf Therapeutics$1.88M43.05-$70.51M-$1.64-1.08Finch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.37 Does the media prefer HOWL or FNCH? In the previous week, Werewolf Therapeutics had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Werewolf Therapeutics and 0 mentions for Finch Therapeutics Group. Werewolf Therapeutics' average media sentiment score of 0.87 beat Finch Therapeutics Group's score of 0.00 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Werewolf Therapeutics Positive Finch Therapeutics Group Neutral Is HOWL or FNCH more profitable? Finch Therapeutics Group's return on equity of -69.14% beat Werewolf Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Werewolf TherapeuticsN/A -111.87% -62.68% Finch Therapeutics Group N/A -69.14%-26.92% Do analysts prefer HOWL or FNCH? Werewolf Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 351.98%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of HOWL or FNCH? 64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryWerewolf Therapeutics beats Finch Therapeutics Group on 11 of the 15 factors compared between the two stocks. Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.35M$347.58M$6.25B$10.65BDividend YieldN/AN/A5.71%4.82%P/E Ratio-1.37N/A30.7530.52Price / SalesN/A495.53585.15186.19Price / CashN/A22.4437.0161.44Price / Book0.853.7412.056.61Net Income-$74.75M-$133.30M$3.33B$277.10M7 Day Performance-0.41%2.51%1.88%2.54%1 Month Performance-4.21%4.48%7.71%3.76%1 Year Performance0.84%0.77%56.33%33.04% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics Group0.8937 of 5 stars$12.05flatN/A+0.4%$19.35MN/A-1.37190HOWLWerewolf Therapeutics3.5224 of 5 stars$1.58-1.9%$8.00+406.6%-42.1%$70.88M$1.88M-0.9540News CoverageAnalyst ForecastCOEPCoeptis Therapeutics0.7944 of 5 stars$14.70-2.1%N/A+255.5%$70.85MN/A-2.532News CoverageAnalyst ForecastShort Interest ↑GANXGain Therapeutics3.2424 of 5 stars$1.94-7.9%$7.86+306.1%-26.1%$69.02M$50K-3.0520Positive NewsOptions VolumeELYMEliem TherapeuticsN/A$2.26-2.6%N/A-57.2%$67.24MN/A-4.269Gap UpHigh Trading VolumeRLMDRelmada Therapeutics2.8308 of 5 stars$2.01-10.5%$1.00-50.1%-42.1%$66.55MN/A-0.9010AADIAadi BioscienceN/A$2.66+20.4%N/A+25.6%$65.69M$25.07M-1.1740High Trading VolumeLITSLite StrategyN/A$1.84-5.6%N/AN/A$65.60M$65.30M-0.39100Positive NewsGap DownABVCABVC BioPharma0.6449 of 5 stars$2.78-4.8%N/A+314.5%$65.45M$391.24K-16.3530News CoveragePositive NewsAnalyst ForecastINKTMiNK Therapeutics2.8705 of 5 stars$14.30-3.8%$37.50+162.2%+106.9%$64.64MN/A-4.9730Positive NewsCRVOCervoMed3.4918 of 5 stars$6.91-4.3%$19.86+187.4%-43.8%$63.73M$9.74M-2.644Analyst Forecast Related Companies and Tools Related Companies HOWL Alternatives COEP Alternatives GANX Alternatives ELYM Alternatives RLMD Alternatives AADI Alternatives LITS Alternatives ABVC Alternatives INKT Alternatives CRVO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FNCH) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.